Skip to content

Panosol 6-3DRecalls & reported problems

Daavlin Distributing CO., The · UVB-680 · Class 2

Adverse event reports
1
Deaths reported
0
Injuries reported
1
Recalls naming it
0

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 00850054882141), received between Dec 13, 2024 and Dec 13, 2024 — classified as 1 injury.

The most frequently reported specific device problem is “Use of Device Problem” (1 report).

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. How this data works · Data updated Oct 13, 2026.

Reports received per month

Nov 2023: 0 reportsDec 2023: 0 reportsJan 2024: 0 reportsFeb 2024: 0 reportsMar 2024: 0 reportsApr 2024: 0 reportsMay 2024: 0 reportsJun 2024: 0 reportsJul 2024: 0 reportsAug 2024: 0 reportsSep 2024: 0 reportsOct 2024: 0 reportsNov 2024: 0 reportsDec 2024: 1 reportsJan 2025: 0 reportsFeb 2025: 0 reportsMar 2025: 0 reportsApr 2025: 0 reportsMay 2025: 0 reportsJun 2025: 0 reportsJul 2025: 0 reportsAug 2025: 0 reportsSep 2025: 0 reportsOct 2025: 0 reportsNov 2025: 0 reportsDec 2025: 0 reportsJan 2026: 0 reportsFeb 2026: 0 reportsMar 2026: 0 reportsApr 2026: 0 reportsMay 2026: 0 reportsJun 2026: 0 reportsJul 2026: 0 reportsAug 2026: 0 reportsSep 2026: 0 reportsOct 2026: 0 reports2024202520261
Last 36 months. The most recent month may be incomplete.

Most reported problems

Device problems

  • Use of Device Problem1
  • Use of Incorrect Control/Treatment Settings1

Patient problems

  • Burn(s)1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • InjuryDec 13, 2024Use of Incorrect Control/Treatment Settings; Use of Device Problem; Use of Incorrect Control/Treatment Settings; Use of Device Problem

    PATIENT HAS BEEN DIAGNOSED WITH PSORIASIS VULGARIS (L40.0). HER DOCTOR PRESCRIBED THE USE OF A PANOSL 63D (ULTRAVIOLET LIGHT THERAPY SYSTEM) TO TREAT HER CONDITION AT HOME BECAUSE OF FREQUENT FLAREUPS OF THE DISEASE. PATIENT WAS ADVISED THAT SHE WOULD NEED 2-3 TREATMENTS PER WEEK AND THAT SHE WOULD BE CONTACTED BY A DOCTOR TO PROVIDE MORE DETAIL REGARDING HER TREATMENT PROTOCOL. UPON RECEIPT OF HER EQUIPMENT, THE PATIENT STILL HAD NOT RECEIVED THE CALL FROM THE PHYSICIAN AND DECIDED TO BEGIN TREATMENT ON HER OWN. USING HER PREVIOUS TANNING EXPERIENCE AS A BASELINE, THE PATIENT DECIDED TO USE AN INITIAL TREATMENT TIME OF SEVEN MINUTES. SHE DID NOT REFER TO THE RECOMMENDED PROTOCOLS INCLUDED IN THE DEVICE OPERATIONS MANUAL NOR CONSULT HER PHYSICIAN OR NATBIO PRIOR TO THE TREATMENT. THIS ARBITRARY TREATMENT TIME DOES NOT CORRESPOND TO THE RECOMMENDED PROTOCOL FOR HER SKIN TYPE (FITZPATRICK SKIN TYPE II) NOR ANY OTHER PHOTOTHERAPY PROTOCOL. AS A RESULT, THE PATIENT RECEIVED FIRST DEGREE BURNS ACROSS HER BODY. SHE SOUGHT TREATMENT FOR HER BURNS AT A LOCAL EMERGENCY ROOM AND WAS PRESCRIBED IBUPROFEN AND PYREGESIC TO TREAT THE INJURIES. HER CURRENT CONDITION IS MUCH IMPROVED WITH SKIN RED

    Patient problems: Burn(s)

    MAUDE report 20925440 ↗

Other LIGHT, ULTRAVIOLET, DERMATOLOGICAL devices

All LIGHT, ULTRAVIOLET, DERMATOLOGICAL devices →

Sources: FDA GUDID, MAUDE and Medical Device Recalls via openFDA. openFDA data is not validated for clinical or regulatory use.